ArticleFrontiers in oncology2025

Durvalumab following definitive chemoradiotherapy among patients with stage III NSCLC in the Thai population: a real-world, multicenter observational study.

Piyada Sitthideatphaiboon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.